Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CNS Pharmaceuticals, Inc. (CNSP)
USD4.68
-0.18 (-3.70%)
US NASDAQ Healthcare Biotechnology
Address
2100 West Loop South 77027
Houston, TX, US
Houston, TX, US
CEO
Rami Levin
Website
cnspharma.com
IPO
2019-11-08
CIK 1729427 ISIN US18978H5081
Description
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.68
-0.18 (-3.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.02
Float Shares
620.3K
Free Float %
108.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.20% | -28.67% | +94.88% | +51.84% | -26.12% | -5.71% | -68.02% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
4.68
Low
0.50
-89.3%
Consensus
0.50
-89.3%
Median
0.50
-89.3%
High
0.50
-89.3%
DCF (Unlevered)
15.50
+231.2%
DCF (Levered)
15.50
+231.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
0.50
-89.3%
|
Quality scores
Altman Z-Score
-43.13
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+92.3% ★ Q1'26: +61.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +751.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,291.9% Q1'26: +197.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 23.20M (-100.0%)
|
40.76M
40.76M – 40.76M
+75.7% YoY
|
50.00M
50.00M – 50.00M
+22.7% YoY
|
76.19M
76.19M – 76.19M
+52.4% YoY
|
—
— – —
-100.0% YoY
|
77.32M
77.32M – 77.32M
|
| EBITDA |
-14.84M
|
-15.83M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-14.84M
|
-15.84M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-14.86M
est: -15.78M (+5.9%)
|
-15.85M
est: -12.16M (-30.3%)
|
-731.6K
-731.6K – -731.6K
+94.0% YoY
|
-736.0K
-736.0K – -736.0K
-0.6% YoY
|
-833.5K
-833.5K – -833.5K
-13.3% YoY
|
-882.3K
-882.3K – -882.3K
-5.9% YoY
|
1.01M
1.01M – 1.01M
+214.6% YoY
|
| SGA |
5.61M
|
6.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-466.44
est: -495.48 (+5.9%)
|
-35.75
est: -27.43 (-30.3%)
|
-1.65
-1.65 – -1.65
+94.0% YoY
|
-1.66
-1.66 – -1.66
-0.6% YoY
|
-1.88
-1.88 – -1.88
-13.3% YoY
|
-1.99
-1.99 – -1.99
-5.9% YoY
|
2.28
2.28 – 2.28
+214.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
6
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cortice Biosciences, Inc. | 573.4K | 5.70% | 573.4K | — | 573.4K | — | CO | — | 2024-08-02 | ↗ |
| 2 | Armistice Capital, LLC | 165.5K | 9.99% | — | 165.5K | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 3 | Steven Boyd | 165.5K | 9.99% | — | 165.5K | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 4 | Waldemar Priebe | 6.7K | 0.30% | — | 6.7K | — | — | IN | US Permanent Resident | 2023-08-01 | ↗ |
| 5 | Kewat, LLC | — | 0.00% | — | — | — | — | OO | US Permanent Resident | 2023-08-01 | ↗ |
| 6 | Robert Forster | — | 0.00% | — | — | — | — | IN | United States | 2024-07-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 37.2K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
38.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+38,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | O'Loughlin Steve | Officer | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | D | ↗ |
| 2026-03-02 | Faulkner Eric | Officer | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | D | ↗ |
| 2026-01-01 | Levin Rami | Director / Officer | A-Award | A | Restricted Stock Units | 19,000 | 0.00 | — | 19,000 | D | ↗ |
| 2025-11-17 | Mahery Amy | Director | A-Award | A | Option to purchase common stock | 1,517 | 12.48 | 18.9K | 1,517 | D | ↗ |
| 2025-11-17 | Keyes Jeffry R. | Director | A-Award | A | Option to purchase common stock | 1,517 | 12.48 | 18.9K | 1,517 | D | ↗ |
| 2025-11-17 | Gumulka Jerzy | Director | A-Award | A | Option to purchase common stock | 1,517 | 12.48 | 18.9K | 1,517 | D | ↗ |
| 2025-11-17 | Downs Christopher | Officer | A-Award | A | Option to purchase common stock | 4,881 | 30.00 | 146.4K | 4,881 | D | ↗ |
| 2025-11-17 | Cockroft Bettina M. | Director | A-Award | A | Option to purchase common stock | 1,517 | 12.48 | 18.9K | 1,517 | D | ↗ |
| 2025-11-17 | Climaco John M | Director / Officer | A-Award | A | Option to purchase common stock | 9,761 | 30.00 | 292.8K | 9,761 | D | ↗ |
| 2025-11-17 | Charles Faith L. | Director | A-Award | A | Option to purchase common stock | 1,517 | 12.48 | 18.9K | 1,517 | D | ↗ |
| 2024-07-30 | Cortice Biosciences, Inc. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-29 | Cortice Biosciences, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 573,368 | — | ↗ |
| 2024-04-08 | Mahery Amy | Director | A-Award | A | Option to purchase common stock | 17,500 | 0.26 | 4.5K | 29,920 | — | ↗ |
| 2024-04-08 | Keyes Jeffry R. | Director | A-Award | A | Restricted Stock Units | 17,500 | 0.00 | — | 80,428 | — | ↗ |
| 2024-04-08 | Gumulka Jerzy | Director | A-Award | A | Option to purchase common stock | 17,500 | 0.26 | 4.5K | 129,594 | — | ↗ |
| 2024-04-08 | Evans Carl Anthony | Director | A-Award | A | Option to purchase common stock | 17,500 | 0.26 | 4.5K | 129,594 | — | ↗ |
| 2024-04-08 | Downs Christopher | Officer | A-Award | A | Option to purchase common stock | 40,000 | 0.26 | 10.3K | 202 | — | ↗ |
| 2024-04-08 | Cockroft Bettina M. | Director | A-Award | A | Option to purchase common stock | 17,500 | 0.26 | 4.5K | 35,574 | — | ↗ |
| 2024-04-08 | Climaco John M | Director / Officer | A-Award | A | Option to purchase common stock | 83,000 | 0.26 | 21.5K | 476,533 | — | ↗ |
| 2024-04-08 | Charles Faith L. | Director | A-Award | A | Option to purchase common stock | 17,500 | 0.26 | 4.5K | 47,315 | — | ↗ |
| 2024-02-01 | Mahery Amy | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-01 | Gumulka Jerzy | Director | A-Award | A | Series B Warrant to purchase common stock | 33,333 | 0.30 | 10.0K | 112,094 | — | ↗ |
| 2024-02-01 | Evans Carl Anthony | Director | A-Award | A | Series A Warrant to purchase common stock | 33,333 | 0.30 | 10.0K | 78,761 | — | ↗ |
| 2024-02-01 | Downs Christopher | Officer | A-Award | A | Series B Warrant to purchase common stock | 66,666 | 0.30 | 20.0K | 161,572 | — | ↗ |
| 2024-02-01 | Climaco John M | Director / Officer | A-Award | A | Series B Warrant to purchase common stock | 166,666 | 0.30 | 50.0K | 393,533 | — | ↗ |
| 2023-09-21 | Keyes Jeffry R. | Director | A-Award | A | Option to purchase common stock | 68,961 | 1.09 | 75.2K | 74,914 | — | ↗ |
| 2023-09-21 | Gumulka Jerzy | Director | A-Award | A | Option to purchase common stock | 39,475 | 1.09 | 43.0K | 45,428 | — | ↗ |
| 2023-09-21 | Evans Carl Anthony | Director | A-Award | A | Option to purchase common stock | 68,961 | 1.09 | 75.2K | 74,914 | — | ↗ |
| 2023-09-21 | Cockroft Bettina M. | Director | A-Award | A | Option to purchase common stock | 16,551 | 1.09 | 18.0K | 74,914 | — | ↗ |
| 2023-09-21 | Charles Faith L. | Director | A-Award | A | Option to purchase common stock | 45,974 | 1.09 | 50.1K | 74,914 | — | ↗ |
| 2023-09-21 | Andraczke Andrzej | Director | A-Award | A | Option to purchase common stock | 39,475 | 1.09 | 43.0K | 45,428 | — | ↗ |
| 2023-09-14 | Cockroft Bettina M. | Director | A-Award | A | Option to purchase common stock | 6,500 | 2.27 | 14.8K | 8,599 | — | ↗ |
| 2023-08-22 | Downs Christopher | Officer | P-Purchase | A | Common Stock | 27,000 | 1.27 | 34.2K | 36,772 | — | ↗ |
| 2023-08-16 | Climaco John M | Director / Officer | P-Purchase | A | Common Stock | 2,750 | 1.80 | 4.9K | 49,010 | — | ↗ |
| 2023-05-05 | Cockroft Bettina M. | Director | A-Award | A | Option to purchase common stock | 2,099 | 1.67 | 3.5K | 2,099 | — | ↗ |
| 2023-05-03 | Cockroft Bettina M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-28 | Downs Christopher | Officer | M-Exempt | D | Restricted Stock Units | 521 | 0.00 | — | 28,248 | — | ↗ |
| 2023-04-28 | Climaco John M | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 46,260 | — | ↗ |
| 2023-04-19 | Gumulka Jerzy | Director | P-Purchase | A | Common Stock | 2,500 | 1.70 | 4.3K | 9,673 | — | ↗ |
| 2023-04-17 | Downs Christopher | Officer | P-Purchase | A | Common Stock | 3,100 | 3.20 | 9.9K | 9,251 | — | ↗ |
| 2023-04-12 | Climaco John M | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.69 | 10.4K | 45,010 | — | ↗ |
| 2023-04-10 | Gumulka Jerzy | Director | P-Purchase | A | Common Stock | 7,173 | 0.74 | 5.3K | 7,173 | — | ↗ |
| 2023-03-29 | Downs Christopher | Officer | A-Award | A | Restricted Stock Units | 6,067 | 0.00 | — | 28,768 | — | ↗ |
| 2023-03-29 | Climaco John M | Director / Officer | A-Award | A | Restricted Stock Units | 16,467 | 0.00 | — | 61,451 | — | ↗ |
| 2023-03-28 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 10,000 | 1.04 | 10.4K | 156,807 | — | ↗ |
| 2023-03-27 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.09 | 5.5K | 166,807 | — | ↗ |
| 2023-03-24 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.08 | 5.4K | 171,807 | — | ↗ |
| 2023-03-23 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 10,000 | 1.08 | 10.8K | 176,807 | — | ↗ |
| 2023-03-22 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.08 | 5.4K | 186,807 | — | ↗ |
| 2023-03-21 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.10 | 5.5K | 191,807 | — | ↗ |
| 2023-03-20 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.08 | 5.4K | 196,807 | — | ↗ |
| 2023-03-17 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.13 | 5.7K | 201,807 | — | ↗ |
| 2023-03-16 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.24 | 6.2K | 206,807 | — | ↗ |
| 2023-03-15 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.22 | 6.1K | 211,807 | — | ↗ |
| 2023-03-14 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.35 | 6.8K | 216,807 | — | ↗ |
| 2023-03-13 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.30 | 6.5K | 221,807 | — | ↗ |
| 2023-03-10 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.29 | 6.5K | 226,807 | — | ↗ |
| 2022-12-30 | Charles Faith L. | Director | A-Award | A | Option to purchase common stock | 3,500 | 0.00 | — | 3,500 | — | ↗ |
| 2022-12-09 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 2,798 | 2.43 | 6.8K | 231,807 | — | ↗ |
| 2022-12-08 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,500 | 2.40 | 13.2K | 234,605 | — | ↗ |
| 2022-12-07 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,500 | 2.46 | 13.5K | 240,105 | — | ↗ |
| 2022-12-06 | Priebe Waldemar | 10% Owner | S-Sale | D | Common Stock | 5,500 | 2.47 | 13.6K | 245,605 | — | ↗ |
| 2022-04-28 | Downs Christopher | Officer | A-Award | A | Restricted Stock Units | 250,000 | 0.00 | — | 681,000 | — | ↗ |
| 2022-04-28 | Climaco John M | Officer | A-Award | A | Restricted Stock Units | 600,000 | 0.00 | — | 1,349,500 | — | ↗ |
| 2022-03-11 | Downs Christopher | Officer | A-Award | A | Common Stock | 33,000 | 0.31 | 10.2K | 184,500 | — | ↗ |
| 2022-03-08 | Evans Carl Anthony | Director | A-Award | A | Common Stock | 3,750 | 0.27 | 1.0K | 3,750 | — | ↗ |
| 2022-03-07 | Keyes Jeffry R. | Director | A-Award | A | Common Stock | 11,100 | 0.30 | 3.3K | 11,100 | — | ↗ |
| 2022-03-07 | Climaco John M | Officer | A-Award | A | Common Stock | 35,000 | 0.28 | 9.8K | 940,298 | — | ↗ |
| 2021-12-06 | Downs Christopher | Officer | P-Purchase | A | Common Stock | 5,000 | 0.94 | 4.7K | 151,500 | — | ↗ |
| 2021-11-19 | Downs Christopher | Officer | P-Purchase | A | Common Stock | 4,500 | 1.15 | 5.2K | 146,500 | — | ↗ |
| 2021-11-16 | Climaco John M | Director / Officer | A-Award | A | Common Stock | 5,000 | 1.28 | 6.4K | 905,298 | — | ↗ |
| 2021-07-15 | Keyes Jeffry R. | Director | A-Award | A | Option to purchase common stock | 32,000 | 1.80 | 57.6K | 178,559 | — | ↗ |
| 2021-07-15 | Gumulka Jerzy | Director | A-Award | A | Option to purchase common stock | 32,000 | 1.80 | 57.6K | 178,559 | — | ↗ |
| 2021-07-15 | Evans Carl Anthony | Director | A-Award | A | Option to purchase common stock | 32,000 | 1.80 | 57.6K | 178,559 | — | ↗ |
| 2021-07-15 | Andraczke Andrzej | Director | A-Award | A | Option to purchase common stock | 32,000 | 1.80 | 57.6K | 178,559 | — | ↗ |
| 2021-02-05 | Downs Christopher | Officer | A-Award | A | Option to purchase common stock (right to buy) | 131,000 | 3.36 | 440.2K | 431,000 | — | ↗ |
| 2021-02-05 | Climaco John M | Director / Officer | A-Award | A | Option to purchase common stock (right to buy) | 310,000 | 3.36 | 1.04M | 749,500 | — | ↗ |
| 2020-08-24 | Downs Christopher | Officer | P-Purchase | A | Common Stock | 142,000 | 2.04 | 289.7K | 142,000 | — | ↗ |
| 2020-06-12 | Keyes Jeffry R. | Director | A-Award | A | Option to purchase common stock | 46,559 | 2.47 | 115.0K | 146,559 | — | ↗ |
| 2020-06-12 | Gumulka Jerzy | Director | A-Award | A | Option to purchase common stock | 46,559 | 2.47 | 115.0K | 146,559 | — | ↗ |
| 2020-06-12 | Evans Carl Anthony | Director | A-Award | A | Option to purchase common stock | 46,559 | 2.47 | 115.0K | 146,559 | — | ↗ |
| 2020-06-12 | Andraczke Andrzej | Director | A-Award | A | Option to purchase common stock | 46,559 | 2.47 | 115.0K | 146,559 | — | ↗ |
| 2020-05-05 | Priebe Waldemar | 10% Owner | J-Other | D | Common Stock | 1,495,867 | 0.00 | — | 7,533,133 | — | ↗ |
| 2019-11-13 | Downs Christopher | Officer | A-Award | A | Option to purchase common stock (right to buy) | 300,000 | 4.00 | 1.20M | 300,000 | — | ↗ |
| 2019-11-07 | Priebe Waldemar | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 9,029,000 | — | ↗ |
| 2019-11-07 | Keyes Jeffry R. | Director | — | D | Option to purchase common stock (right to buy) | 100,000 | 1.50 | 150.0K | 0 | — | ↗ |
| 2019-11-07 | Gumulka Jerzy | Director | — | D | Option to purchase common stock (right to buy) | 100,000 | 0.05 | 4.5K | 0 | — | ↗ |
| 2019-11-07 | Evans Carl Anthony | Director | — | D | Option to purchase common stock (right to buy) | 100,000 | 1.50 | 150.0K | 0 | — | ↗ |
| 2019-11-07 | Climaco John M | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 900,000 | — | ↗ |
| 2019-11-07 | Andraczke Andrzej | Director | — | D | Option to purchase common stock (right to buy) | 100,000 | 1.50 | 150.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
574.6K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | John Climaco, Chief Executive Officer | 525.0K | — | — | 292.8K | 285.9K | — | 1.10M | 26.53% | ↗ |
| 2 | 2024 | Christopher Downs, Chief Financial Officer | 340.0K | — | — | 146.4K | 134.6K | — | 621.1K | 23.57% | ↗ |
| 3 | 2024 | Sandra Silberman, Chief Medical Officer | 200.0K | — | — | 73.2K | 88.4K | — | 361.6K | 20.24% | ↗ |
| 4 | 2023 | John Climaco, Chief Executive Officer | 525.0K | — | 20.7K | 18.0K | 60.6K | — | 624.3K | 6.20% | ↗ |
| 5 | 2023 | Christopher Downs, Chief Financial Officer | 340.0K | — | 10.3K | 9.0K | 42.2K | — | 401.5K | 4.82% | ↗ |
| 6 | 2023 | Sandra Silberman, Chief Medical Officer | 200.0K | — | 4.8K | 4.2K | 61.2K | — | 270.2K | 3.31% | ↗ |
| 7 | 2022 | John Climaco, Chief Executive Officer | 525.0K | — | — | 14.2K | 288.8K | — | 827.9K | 1.71% | ↗ |
| 8 | 2022 | Christopher Downs, Chief Financial Officer | 340.0K | — | — | 5.2K | 136.0K | — | 481.2K | 1.09% | ↗ |
| 9 | 2022 | Sandra Silberman, Chief Medical Officer | 200.0K | — | — | 1.3K | 80.0K | — | 281.3K | 0.46% | ↗ |
| 10 | 2021 | John Climaco, Chairman and Chief Executive Officer | 525.0K | — | 197.9K | — | 123.0K | — | 845.9K | 23.40% | ↗ |
| 11 | 2021 | Christopher Downs, Chief Financial Officer | 340.0K | — | 82.5K | — | 58.0K | — | 480.5K | 17.17% | ↗ |
| 12 | 2021 | Sandra Silberman, Chief Medical Officer | 200.0K | 10.0K | 41.2K | — | 18.0K | — | 269.2K | 15.32% | ↗ |
| 13 | 2020 | John Climaco, Chairman and Chief | 440.0K | — | — | 937.8K | 195.1K | — | 1.57M | 59.62% | ↗ |
| 14 | 2020 | John Climaco, Chairman and Chief Executive Officer | 440.0K | — | — | — | 195.1K | — | 1.57M | 0.00% | ↗ |
| 15 | 2020 | Christopher Downs, Chief Financial Officer | 300.0K | — | — | 396.3K | 94.7K | — | 791.0K | 50.10% | ↗ |
| 16 | 2020 | Christopher Downs, Chief Financial Officer | 300.0K | — | — | — | 94.7K | — | 791.0K | 0.00% | ↗ |
| 17 | 2020 | Sandra Silberman, Chief Medical Officer | 175.0K | — | — | — | 38.9K | — | 341.0K | 0.00% | ↗ |
| 18 | 2020 | Sandra Silberman, Chief Medical Officer | 175.0K | — | — | 127.1K | 38.9K | — | 341.0K | 37.27% | ↗ |
| 19 | 2019 | John Climaco, Chairman and Chief | 213.9K | 193.6K | — | 806.2K | — | 15.6K | 1.23M | 65.58% | ↗ |
| 20 | 2019 | John Climaco, Chairman and Chief Executive Officer | 213.9K | 193.6K | — | 806.2K | — | 15.6K | 1.23M | 65.58% | ↗ |
| 21 | 2019 | Christopher Downs, Chief Financial Officer | 40.0K | 25.0K | — | 1.09M | — | 3.4K | 1.15M | 94.07% | ↗ |
| 22 | 2019 | Christopher Downs, Chief Financial Officer | 40.0K | 25.0K | — | 1.09M | — | 3.4K | 1.15M | 94.07% | ↗ |
| 23 | 2019 | Sandra Silberman, Chief Medical Officer | 23.3K | 20.1K | — | 229.3K | — | — | 272.7K | 84.08% | ↗ |
| 24 | 2019 | Sandra Silberman, Chief Medical Officer | 23.3K | 20.1K | — | 229.3K | — | — | 272.7K | 84.08% | ↗ |
| 25 | 2018 | John Climaco, Chairman and Chief Executive Officer | 150.0K | — | — | — | — | 14.3K | 164.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rami Levin | Chief Executive Officer, President & Director | 810.9K | male |
| Christopher S. Downs FP&A | Senior Vice President of Finance | 594.0K | male |
| Steve O'Loughlin | Chief Financial Officer | 474.6K | male |
| E. Lynne Kelley | Chief Medical Officer | 288.4K | — |
| Lynne Kelley | Chief Medical Officer | 288.4K | — |
| Eric Faulkner | Chief Technology Officer | — | male |
| Dylan Wenke | Chief Business Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNSP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
